Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome

• Published in: Science translational medicine Vol. 12; no. 572
• Main Authors: Rom, Oren, Liu, Yuhao, Liu, Zhipeng, Zhao, Ying, Wu, Jianfeng, Ghrayeb, Alia, Villacorta, Luis, Fan, Yanbo, Chang, Lin, Wang, Lu, Liu, Cai, Yang, Dongshan, Song, Jun, Rech, Jason C, Guo, Yanhong, Wang, Huilun, Zhao, Guizhen, Liang, Wenying, Koike, Yui, Lu, Haocheng, Koike, Tomonari, Hayek, Tony, Pennathur, Subramaniam, Xi, Chuanwu, Wen, Bo, Sun, Duxin, Garcia-Barrio, Minerva T, Aviram, Michael, Gottlieb, Eyal, Mor, Inbal, Liu, Wanqing, Zhang, Jifeng, Chen, Y Eugene
• Format: Journal Article
• Language: English
• Published: United States 02.12.2020
• Subjects: Animals; Diet, High-Fat; Fatty Acids; Gastrointestinal Microbiome; Glutathione; Glycine; Humans; Liver; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease - drug therapy

Nonalcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH) has reached epidemic proportions with no pharmacological therapy approved. Lower circulating glycine is consistently reported in patients with NAFLD, but the causes for reduced glycine, its role as a causative fac...